OR WAIT 15 SECS
January 05, 2016.
The global breast cancer therapeutics market is set to increase in value from $10.4 billion in 2014 to $17.2 billion by 2021, at a CAGR of 7.3%, according to GBI Research.
The company’s latest report states that this strong growth will be primarily due to substantial increases in the prevalence of breast cancer, with rates of the disease expected to rise over the forecast period due to an aging population, changing lifestyles and higher survival rates.
GBI analyst Deekshita Allavarapu commented: “In terms of upcoming breast cancer treatments, the overall pipeline is strong, with 743 products, and the early pipeline has many experimental molecules designed to target novel pathways. Promising pipeline drugs include abemaciclib, buparlisib, LEE 011, Olaparib and NeuVax, all of which are expected to be approved within the forecast period and have demonstrated significant clinical benefits in trials. In addition, rapid uptake of premium-priced biologics, such as Perjeta and Kadcyla, in all settings of the disease will contribute to the market growth.”
GBI's report also states however that the market will face some limitations due to patent expirations for a number of key drugs, including Afinitor, Avastin and Herceptin. However, the use of combinations of branded therapies in both the early-stage and metastatic settings will increase the annual cost of therapy and offset the impact of patent expiries.